A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind, randomized, placebo-controlled, 2-way crossover study to
evaluate the safety of CVT-301 levodopa (l-dopa) when co- administered with the first daily
dose of oral levodopa/carbidopa for early morning OFF symptoms in patients with Parkinson's
disease (PD).